Anticoagulation Therapy Timing in Patients with Atrial Fibrillation after Subdural Haematoma
Study Overview
This study focuses on patients with subdural haematomas (SDHs) who need anticoagulant therapy for atrial fibrillation. Currently, there are no guidelines on when to safely resume anticoagulation after an SDH. Our research aims to explore if it is safe to start anticoagulation therapy sooner (30 days) or later (3 months) after the diagnosis of SDH.
Study Design
This pilot study will involve adults diagnosed with acute or chronic SDH, whether they have other bleeding or not. Participants will be randomly assigned to start their anticoagulant therapy at different times. We will evaluate:
- How many patients can be recruited
- Adherence to the study protocol
- Patients’ compliance with their assigned treatment
Expected Outcomes
We will also look at how well patients do functionally and any safety issues that arise. The findings will help shape a larger trial to understand the best timing for resuming anticoagulation therapy after SDH, addressing a significant clinical challenge.
Ethics and Future Plans
This study has received ethical approval and follows established guidelines to ensure patient safety. Informed consent will be obtained from all participants. The data collected will inform future studies.
Trial Registration
Registered under number: NCT05472766.
Importance of Clinical Trials
Clinical trials are essential for developing new treatments. They aim to incorporate research findings directly into everyday medical practice.
Innovative Solutions with AI
Our AI platform, DocSym, combines essential medical standards and research into a single resource for healthcare providers. This streamlines operations through mobile apps that support:
- Scheduling appointments
- Monitoring patient treatments
- Telemedicine services
Benefits of Using AI
By adopting AI, clinics can improve efficiency, enhance patient outcomes, and reduce paperwork. Discover how we can assist at aidevmd.com.
